Q2 2026 INVO Fertility Inc Earnings Call Transcript
Key Points
- Revenue increased 17% year-over-year to $2.2 million in Q2 2026, driven by the full-quarter contribution from Family Beginnings and organic growth.
- Clinic-level Adjusted EBITDA improved to $333,000 in Q2 2026, up from $164,000 in Q1 2026, demonstrating a profitable operating base.
- The company simplified its capital structure by converting or retiring all Series C2 preferred stock, eliminating warrant liabilities, and raising $7.1 million in net proceeds from warrant exercises.
- INVO Fertility Inc (IVF) regained compliance with Nasdaq's timely filing requirement by completing delayed 10-K and 10-Q filings, enhancing transparency and credibility.
- The acquisition of the remaining ownership interests in the Birmingham clinic increases operational control and consolidates its results, boosting future earnings potential.
- Consolidated Adjusted EBITDA remained negative at approximately -$1.0 million in Q2 2026, reflecting ongoing corporate and public company costs.
- The company continues to require additional capital to fund operations and growth, as evidenced by the new $15 million equity purchase facility with Alumni Capital.
- Net cash used in operating activities was $3.0 million in the first half of 2026, indicating persistent cash burn despite improvements.
- Cost of services increased to $1.4 million in Q2 2026, partly due to one-time staffing costs at the Georgia clinic, pressuring margins.
- The company's reliance on acquisitions for growth carries integration risks, and the pipeline's success is not guaranteed, as acknowledged by management.
Hello and welcome to INVO Fertility second quarter fiscal year 2026 financial results conference call. (Operator Instructions) Please note, this event is being recorded. I would now like to turn the call over to Robert Bloom of Lithium Partners. Mr. Bloom, please go ahead.
All right, wonderful. Thank you very much, Gary, and thank you all for joining us today to discuss INVO Fertility's second quarter 2026 financial results, and this is for the period ended June 30, 2026. With us on the call today are Steve Shum, the company's Chief Executive Officer, and Terah Krigsvold, the company's Chief Financial Officer. (Event Instructions)
Before we begin, we submit for the record the following statement. Statements made by the management team of INVO Fertility during the course of this conference call may contain forward-looking statements within the meaning of the federal securities laws. These statements describe future expectations, plans, results or strategies, and are generally identified by words such as may, will,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
